MANGOCEUTICALS, INC. current report, 10 December 2023

Vollständiges Dokument

Mangoceuticals, Inc. — Form 8-K Summary

Business Context and Reporting Period

Mangoceuticals, Inc. filed a Form 8-K on December 11, 2023, reporting an agreement entered into on December 10, 2023. The company operates a telehealth platform through MangoRx.com and is listed on Nasdaq under the symbol MGRX.

Material Agreement and Equity Issuance

  • Mangoceuticals entered into a Marketing Agreement with Marius Pharmaceuticals, LLC for the use of the “Kyzatrex” trademark and related marks for branding, packaging, marketing, and selling oral testosterone undecanoate softgel capsules in the United States.
  • The license is non-exclusive, non-transferable, and royalty-free, and applies to sales through MangoRx.com and its telehealth platform.
  • In consideration for the license, Mangoceuticals issued Marius 100,000 restricted common shares, fully earned upon execution of the agreement.
  • The issuance was reported as exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D.

Term, Performance Requirements, and Termination

  • The initial agreement term is two years, with automatic one-year renewals unless terminated.
  • Marius may terminate if Mangoceuticals does not have at least 2,500 monthly Kyzatrex customers at least 30 days before the end of the initial term.
  • Marius may terminate without cause on at least 60 days’ prior written notice.
  • Marius may also terminate if Mangoceuticals has not achieved at least 30% of the 2,500-customer threshold within six months after launch.
  • The Kyzatrex launch on the MangoRx website was anticipated on or before January 31, 2024.
  • Following termination, Mangoceuticals must cease use of the Marius Marks and remove related references from promotional materials within the specified period.
  • During the agreement and for 12 months afterward, Mangoceuticals agreed not to promote another product containing testosterone undecanoate.

Financial Metrics, Outlook, and Risks

The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, nor does it provide formal financial guidance.

  • The agreement creates a launch and customer-acquisition requirement tied to continued access to the Kyzatrex marks.
  • Failure to reach the specified subscriber thresholds could result in termination.
  • Marius retains broad termination rights, including termination without cause.
  • The product launch timing was anticipated rather than reported as completed.
  • The restricted share issuance may dilute existing shareholders; the filing does not state the shares’ fair value or quantified dilution impact.

Key Facts for Investors to Verify

  • Whether the Kyzatrex product launched by January 31, 2024.
  • Actual monthly Kyzatrex customer counts and progress toward the 2,500-customer requirement.
  • Whether the agreement remains in effect and has been renewed or terminated.
  • The accounting treatment and fair value assigned to the 100,000 restricted shares issued to Marius.
  • Any subsequent disclosures regarding revenue, costs, regulatory matters, or risks associated with Kyzatrex sales.